A versatile and highly effective platform remains a major challenge in the development of
personalized cancer vaccines. Here, we devised a redox-responsive polycondensate …

Specific neoantigens are promising candidates for personalized cancer vaccines and
immunotherapies, whereas the low immunogenicity and physicochemical variability are the …

Cancer vaccines targeting patient-specific neoantigens have emerged as a promising
strategy for improving responses to immune checkpoint blockade. However, neoantigenic …

Cancer vaccines targeting tumor specific neoantigens derived from nonsynonymous
mutations of tumor cells have emerged as an effective approach to induce antitumor T cells …

Introduction Cancer vaccine represents a promising strategy toward personalized
immunotherapy, and its therapeutic potency highly relies on the specificity of tumor antigens …

Peptide vaccines are broadly used as alternatives to traditional vaccines for cancer
immunotherapy; however, the clinical translation of peptide vaccination is still limited by the …

Neoantigen cancer vaccines have been envisioned as one of the most promising means for
cancer therapies. However, identifying neoantigens for tumor types with low tumor mutation …

Personalized cancer vaccines hold promises for future cancer therapy. Targeting
neoantigens is perceived as more beneficial compared to germline, non-mutated antigens …

Personalized cancer vaccines targeting patient-specific neoantigens are a promising cancer
treatment modality; however, neoantigen physicochemical variability can present challenges …

Background Harnessing the immune system to purposely recognize and destroy tumors
represents a significant breakthrough in clinical oncology. Non-synonymous mutations …